For: | Lee S, Saffo S. Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol 2023; 29(1): 61-74 [PMID: 36683719 DOI: 10.3748/wjg.v29.i1.61] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v29/i1/61.htm |
Number | Citing Articles |
1 |
J.A. Velarde-Ruiz Velasco, J. Crespo, A. Montaño-Loza, J.M. Aldana-Ledesma, A.D. Cano-Contreras, E. Cerda-Reyes, N.J. Fernández Pérez, G.E. Castro-Narro, E.S. García-Jiménez, J.E. Lira-Vera, Y.I. López-Méndez, J. Meza-Cardona, R. Moreno-Alcántar, J. Pérez-Escobar, J.L. Pérez-Hernández, D.K. Tapia-Calderón, F. Higuera-de-la-Tijera. Position paper on perioperative management and surgical risk in the patient with cirrhosis. Revista de Gastroenterología de México (English Edition) 2024; 89(3): 418 doi: 10.1016/j.rgmxen.2024.05.001
|
2 |
Maxine W. Stachel, Eugene C. DePasquale. Optimizing cardiac status in the preliver transplant candidate. Current Opinion in Organ Transplantation 2024; 29(1): 50 doi: 10.1097/MOT.0000000000001119
|
3 |
Wanting Yang, Gaoyue Guo, Chao Sun. Therapeutic potential of rifaximin in liver diseases. Biomedicine & Pharmacotherapy 2024; 178: 117283 doi: 10.1016/j.biopha.2024.117283
|
4 |
Larisse Longo, Gabriel Guerreiro, Luiza Behrens, Matheus Pereira, Carlos Pinzon, Carlos Cerski, Carolina Uribe‑Cruz, Mário Álvares‑da‑Silva. Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal model. Biomedical Reports 2024; 22(1) doi: 10.3892/br.2024.1882
|
5 |
Aldo Torre, Jacqueline Córdova-Gallardo, Alberto C Frati Munari. Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier. Therapeutics and Clinical Risk Management 2023; : 839 doi: 10.2147/TCRM.S425292
|
6 |
J.A. Velarde-Ruiz Velasco, J. Crespo, A. Montaño-Loza, J.M. Aldana-Ledesma, A.D. Cano-Contreras, E. Cerda-Reyes, N.J. Fernández Pérez, G.E. Castro-Narro, E.S. García-Jiménez, J.E. Lira-Vera, Y.I. López-Méndez, J. Meza-Cardona, R. Moreno-Alcántar, J. Pérez-Escobar, J.L. Pérez-Hernández, D.K. Tapia-Calderón, F. Higuera-de-la-Tijera. Posicionamiento sobre manejo perioperatorio y riesgo quirúrgico en el paciente con cirrosis. Revista de Gastroenterología de México 2024; 89(3): 418 doi: 10.1016/j.rgmx.2024.05.001
|
7 |
Xiangfeng Zeng, Sheiladevi Sukumaran. Research progress on the relationship between intestinal flora and liver cirrhosis. International Conference on Modern Medicine and Global Health (ICMMGH 2023) 2023; : 87 doi: 10.1117/12.2692644
|
8 |
Yong He, Lu Chai, Han Chen, Xing-Shun Qi. Effect of different infusion approaches on safety and efficacy of terlipressin: Current controversies. World Chinese Journal of Digestology 2023; 31(17): 705 doi: 10.11569/wcjd.v31.i17.705
|
9 |
Christos Siafarikas, Chris J. Kapelios, Margarita Papatheodoridi, John Vlachogiannakos, Nikolaos Tentolouris, George Papatheodoridis. Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use. Liver International 2024; 44(4): 884 doi: 10.1111/liv.15851
|
10 |
Xue Li, Shi Liu, Jin Li, Ning Liu, Hui Li, An Ge, Liang Wang, Xie Dong, Hui Wang, Ju Liu, Lin Zhang, Hao Dong Zhang, Wei Gou. Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension. International Journal of General Medicine 2024; : 1493 doi: 10.2147/IJGM.S453107
|